Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 7, 2014, Pages 1750-1757

  Gharpure, Kshipra M ^a,b   Chu, Kevin S ^d   Bowerman, Charles J ^c,d   Miyake, Takahito ^a   Pradeep, Sunila ^a   Mangala, Selanere L ^a   Han, Hee Dong ^a,g   Rupaimoole, Rajesha ^a,b   Armaiz Pena, Guillermo N ^a   Rahhal, Tojan B ^d   Wu, Sherry Y ^a   Luft, J Christopher ^c,d   Napier, Mary E ^f   Lopez Berestein, Gabriel ^a   DeSimone, Joseph M ^c,d,e   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g Konkuk University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD31 ANTIGEN; DOCETAXEL; KI 67 ANTIGEN; NANOCARRIER; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; EZH2 PROTEIN, HUMAN; NANOPARTICLE; POLYCOMB REPRESSIVE COMPLEX 2; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER TISSUE; CAPILLARY DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; DOSE CALCULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG RELEASE; DRUG RESPONSE; FEMALE; IN VIVO STUDY; INTERNALIZATION; METRONOMIC DRUG ADMINISTRATION; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; OVARY CARCINOMA; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; TUMOR VOLUME; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; GENE SILENCING; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR CELL LINE;

ADMINISTRATION, METRONOMIC; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; GENE SILENCING; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; OVARIAN NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, SMALL INTERFERING; TAXOIDS;

EID: 84904164280     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0930     Document Type: Article

References (21)

1. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-16. (Pubitemid 37328838)
2. Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2001;2:733-40. (Pubitemid 33134058)
3. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-7. (Pubitemid 30217688)
4. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36. (Pubitemid 38745528)
5. Romiti A, Cox MC, Sarcina I, Rocco R, D'Antonio C, Barucca V, et al. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother Pharmacol 2013;72:13-33.
6. Enlow EM, Luft JC, Napier ME, DeSimone JM. Potent engineered PLGA nanoparticles by virtue of exceptionally high chemotherapeutic loadings. Nano Lett 2011;11:808-13.
7. Chu KS, Hasan W, Rawal S, Walsh MD, Enlow EM, Luft JC, et al. Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. Nanomedicine 2013;9:686-93.
8. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007;67:1757-68. (Pubitemid 46383403)
9. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010;18:185-97.
10. Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, et al. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 2010;9:985-95.
11. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24. (Pubitemid 30217701)
12. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86. (Pubitemid 30207647)
13. Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007;67:281-8. (Pubitemid 46142786)
14. Merritt WM, Danes CG, Shahzad MMK, Lin YG, Kamat AA, Han LY, et al. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 2009;8:1596-603.
15. Aigner J, Bischofs E, Hallscheidt P, Sohn C, Schneeweiss A, Eichbaum M. Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment. Anticancer Drug 2011;22:1030-3.
16. Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 2010;9:996-1006.
17. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-7.
18. Guo J, Cai J, Yu L, Tang H, Chen C, Wang Z. EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo. Cancer Sci 2011;102:530-9.
19. Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF, et al. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-β1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 2010;31:1576-83.
20. Seward S, Semaan A, Qazi AM, Gruzdyn OV, Chamala S, Bryant CC, et al. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21waf1/cip1 and by inhibiting mutant p53. Cancer Lett 2013;336:53-60.
21. Tsang DPF, ChengASL. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol 2011;26:19-27.